These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6765 related articles for article (PubMed ID: 24660121)

  • 21. miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways.
    Sun X; Li J; Sun Y; Zhang Y; Dong L; Shen C; Yang L; Yang M; Li Y; Shen G; Tu Y; Tao J
    Oncotarget; 2016 Aug; 7(33):53558-53570. PubMed ID: 27448964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAF
    Torres-Collado AX; Knott J; Jazirehi AR
    Cancers (Basel); 2018 May; 10(6):. PubMed ID: 29795041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular Analysis of Elements of Melanoma Insensitivity to TCR-Engineered Adoptive Cell Therapy.
    Jazirehi AR
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased CD271 expression by the NF-kB pathway promotes melanoma cell survival and drives acquired resistance to BRAF inhibitor vemurafenib.
    Lehraiki A; Cerezo M; Rouaud F; Abbe P; Allegra M; Kluza J; Marchetti P; Imbert V; Cheli Y; Bertolotto C; Ballotti R; Rocchi S
    Cell Discov; 2015; 1():15030. PubMed ID: 27462428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors.
    Shi H; Moriceau G; Kong X; Koya RC; Nazarian R; Pupo GM; Bacchiocchi A; Dahlman KB; Chmielowski B; Sosman JA; Halaban R; Kefford RF; Long GV; Ribas A; Lo RS
    Cancer Discov; 2012 May; 2(5):414-24. PubMed ID: 22588879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
    Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma.
    Duggan MC; Stiff AR; Bainazar M; Regan K; Olaverria Salavaggione GN; Maharry S; Blachly JS; Krischak M; Walker CJ; Latchana N; Tridandapani S; de la Chapelle A; Eisfeld AK; Carson WE
    Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9629-9634. PubMed ID: 28827320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on
    Frazao A; Colombo M; Fourmentraux-Neves E; Messaoudene M; Rusakiewicz S; Zitvogel L; Vivier E; Vély F; Faure F; Dréno B; Benlalam H; Bouquet F; Savina A; Pasmant E; Toubert A; Avril MF; Caignard A
    Cancer Immunol Res; 2017 Jul; 5(7):582-593. PubMed ID: 28576831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells.
    Atay C; Kwak T; Lavilla-Alonso S; Donthireddy L; Richards A; Moberg V; Pilon-Thomas S; Schell M; Messina JL; Rebecca VW; Xiao M; Tan J; Zhang G; Weber JS; Herlyn M; Sarnaik AA; Gabrilovich DI
    Clin Cancer Res; 2019 May; 25(9):2783-2794. PubMed ID: 30765391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anaplastic Lymphoma Kinase Confers Resistance to BRAF Kinase Inhibitors in Melanoma.
    Janostiak R; Malvi P; Wajapeyee N
    iScience; 2019 Jun; 16():453-467. PubMed ID: 31229894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of BRAF V600 mutation in melanoma.
    Ascierto PA; Kirkwood JM; Grob JJ; Simeone E; Grimaldi AM; Maio M; Palmieri G; Testori A; Marincola FM; Mozzillo N
    J Transl Med; 2012 Jul; 10():85. PubMed ID: 22554099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.
    Massi D; Brusa D; Merelli B; Falcone C; Xue G; Carobbio A; Nassini R; Baroni G; Tamborini E; Cattaneo L; Audrito V; Deaglio S; Mandalà M
    Ann Oncol; 2015 Sep; 26(9):1980-1987. PubMed ID: 26037795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HI-511 overcomes melanoma drug resistance
    Chang X; Zhang T; Wang Q; Rathore MG; Reddy K; Chen H; Shin SH; Ma WY; Bode AM; Dong Z
    Theranostics; 2020; 10(21):9721-9740. PubMed ID: 32863956
    [No Abstract]   [Full Text] [Related]  

  • 35. Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting.
    Carroll MJ; Parent CR; Page D; Kreeger PK
    BMC Cancer; 2019 Oct; 19(1):1025. PubMed ID: 31672130
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
    Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
    [No Abstract]   [Full Text] [Related]  

  • 37. YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma.
    Kim MH; Kim CG; Kim SK; Shin SJ; Choe EA; Park SH; Shin EC; Kim J
    Cancer Immunol Res; 2018 Mar; 6(3):255-266. PubMed ID: 29382670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma.
    Hu W; Jin L; Jiang CC; Long GV; Scolyer RA; Wu Q; Zhang XD; Mei Y; Wu M
    Cell Death Dis; 2013 Nov; 4(11):e914. PubMed ID: 24201813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors.
    Escuin-Ordinas H; Atefi M; Fu Y; Cass A; Ng C; Huang RR; Yashar S; Comin-Anduix B; Avramis E; Cochran AJ; Marais R; Lo RS; Graeber TG; Herschman HR; Ribas A
    Mol Oncol; 2014 Mar; 8(2):250-60. PubMed ID: 24345644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway.
    Koetz-Ploch L; Hanniford D; Dolgalev I; Sokolova E; Zhong J; Díaz-Martínez M; Bernstein E; Darvishian F; Flaherty KT; Chapman PB; Tawbi H; Hernando E
    Pigment Cell Melanoma Res; 2017 May; 30(3):328-338. PubMed ID: 28140520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 339.